Medexus Pharmaceuticals (TSE:MDP) Upgraded to Strong-Buy at Leede Financial

Medexus Pharmaceuticals (TSE:MDP) was upgraded by research analysts at Leede Financial from a “moderate buy” rating to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.29 EPS, FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

Several other research analysts have also recently issued reports on MDP. Stifel Nicolaus raised their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research note on Wednesday, January 8th. Finally, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. One analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Trading Up 19.0 %

TSE MDP opened at C$4.75 on Wednesday. The stock has a market cap of C$116.52 million, a P/E ratio of 95.00 and a beta of 1.96. The company has a fifty day simple moving average of C$3.14 and a two-hundred day simple moving average of C$2.69. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.